Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
AnPac Bio-Medical Science Co., Ltd. - American Depositary Shares
Asia Broadband Inc
Caduceus Software Systems Corp
Clean Vision Corporation
Currenc Group Inc. - Ordinary Shares
Essential Utilities, Inc. Common Stock
Femasys Inc. - Common Stock
ITHAX Acquisition Corp. - Class A Ordinary Shares
MIND Technology, Inc. - Common Stock
Medigus Ltd. - American Depositary Shares
Metawells Oil & Gas Inc
Minim, Inc. - Common Stock
Novo Integrated Sciences, Inc. - Common Stock
Nutranomics Inc
Om Holdings International Inc
Phunware, Inc. - Common Stock
Rapid Nutrition Ord Shs
Safe-T Group Ltd. - American Depositary Shares
Soligenix, Inc. - Common Stock
TRACON Pharmaceuticals, Inc. - Common Stock
Edit Watchlist
Top Indices
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
My Portfolio
Articles published by Gain Therapeutics, Inc.
< Previous
1
2
3
Next >
Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
November 10, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
November 05, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
October 08, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
October 01, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
September 29, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
September 17, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
August 25, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
August 11, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
July 16, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
June 29, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
June 10, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
May 26, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
May 11, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
April 24, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
March 26, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Present at the 38th Annual ROTH Conference
March 19, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
March 18, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
March 12, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
January 07, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
January 06, 2026
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
December 18, 2025
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
December 18, 2025
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
November 20, 2025
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
November 12, 2025
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Present at Neuroscience 2025
October 30, 2025
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
October 16, 2025
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
October 09, 2025
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
October 06, 2025
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
September 23, 2025
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.